eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
5/2024
vol. 41
 
Share:
Send email
Share:
Letter to the Editor

Adult-onset atopic dermatitis induced by vedolizumab: a case series

Eleonora Nucera
1
,
Sara Urbani
1
,
Arianna Aruanno
1
,
Franco Scaldaferri
2
,
Dario D’Urso
3
,
Clara De Simone
3

  1. Allergy Unit of “Fondazione Policlinico Universitario A.Gemelli IRCCS”, Rome, Italy
  2. Digestive Disease Center, Medical and Surgical Sciences Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
  3. Dermatology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Adv Dermatol Allergol 2024; XLI (5): 542-544
DOI: https://doi.org/10.5114/ada.2024.144405
Online publish date: 2024/10/23
Article file
- Adult.pdf  [0.11 MB]
Get citation
 
 
1. Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009; 330: 864-75.
2. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711-21.
3. Chaparro M, Garre A, Ricart E, et al.; GETECCU study group. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Aliment Pharmacol Ther 2018; 48: 839-51.
4. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017; 66: 839-51.
5. Tofte SJ, Graeber M, Cherill R, et al. Eczema area and severity index (EASI): a new tool to evaluate atopic dermatitis. J Eur Acad Dermatol Venereol 1998; 11: S197.
6. Simpson E, Bissonnette R, Eichenfield LF, et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol 2020; 83: 839-46.
7. Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993; 74: 185-5.
8. Hamann A, Andrew DP, Jablonski-Westrich D, et al. Role of alpha 4- integrins in lymphocyte homing to mucosal tissues in vivo. J Immunol 1994; 152: 3282-93.
9. Leung E, Kanwar RK, Kanwar JR, et al. Mucosal vascular addressin cell adhesion molecule-1 is expressed outside the endothelial lineage on fibroblasts and melanoma cells. Immunol Cell Biol 2003; 81: 320-7.
10. Loftus EV Jr, Feagan BG, Panaccione R, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther 2020; 52: 1353-65.
11. Baumgart DC, Bokemeyer B, Drabik A, et al.; Vedolizumab Germany Consortium. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice: a nationwide consecutive German cohort study. Aliment Pharmacol Ther 2016; 43: 1090-102.
12. Gilhooley E, Doherty G, Lally A. Vedolizumab-induced acne in inflammatory bowel disease. Int J Dermatol 2018; 57: 752-3.
13. Garbo GM, Renna S, Caputo V, et al. Letter: psoriasiform eruption during vedolizumab therapy. Aliment Pharmacol Ther 2019; 50: 342-3.
14. He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol 2019; 20: 181-92.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.